$902.71
1.10% day before yesterday
NYSE, Sep 06, 10:05 pm CET
ISIN
US5324571083
Symbol
LLY
Sector
Industry

Eli Lilly and Company Stock price

$902.71
+109.53 13.81% 1M
+122.94 15.77% 6M
+319.79 54.86% YTD
+342.76 61.21% 1Y
+643.18 247.82% 3Y
+788.66 691.50% 5Y
+837.71 1,288.78% 10Y
NYSE, Closing price Fri, Sep 06 2024
-10.04 1.10%
ISIN
US5324571083
Symbol
LLY
Sector
Industry

Key metrics

Market capitalization $857.96b
Enterprise Value $883.56b
P/E (TTM) P/E ratio 112.76
EV/FCF (TTM) EV/FCF 3,427.31
EV/Sales (TTM) EV/Sales 22.70
P/S ratio (TTM) P/S ratio 22.04
P/B ratio (TTM) P/B ratio 63.29
Dividend yield 0.50%
Last dividend (FY23) $4.52
Revenue growth (TTM) Revenue growth 31.87%
Revenue (TTM) Revenue $38.92b
EBIT (operating result TTM) EBIT $13.43b
Free Cash Flow (TTM) Free Cash Flow $257.80m
Cash position $3.36b
EPS (TTM) EPS $8.01
P/E forward 57.80
P/S forward 18.68
EV/Sales forward 19.23
Short interest 0.79%
Show more

Is Eli Lilly and Company a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Eli Lilly and Company Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Eli Lilly and Company forecast:

25x Buy
81%
5x Hold
16%
1x Sell
3%

Analyst Opinions

31 Analysts have issued a Eli Lilly and Company forecast:

Buy
81%
Hold
16%
Sell
3%

Financial data from Eli Lilly and Company

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
38,923 38,923
32% 32%
100%
- Direct Costs 7,492 7,492
14% 14%
19%
31,431 31,431
37% 37%
81%
- Selling and Administrative Expenses 6,184 6,184
13% 13%
16%
- Research and Development Expense 10,206 10,206
25% 25%
26%
15,041 15,041
61% 61%
39%
- Depreciation and Amortization 1,614 1,614
10% 10%
4%
EBIT (Operating Income) EBIT 13,427 13,427
70% 70%
34%
Net Profit 7,342 7,342
13% 13%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Eli Lilly and Company directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eli Lilly and Company Stock News

Positive
24/7 Wall Street
one day ago
Unless you have been living under the rock, you'd have heard of Nvidia's (NASDAQ: NVDA) success story.
Positive
Investors Business Daily
one day ago
Biotech stocks have been rallying as funds load up. Five stocks have been outperforming the vast majority in the IBD database.
Positive
Reuters
one day ago
Eli Lilly's experimental next generation weight-loss drug mimics three hormones instead of just one or two and continues to show promising clinical trial results for additional health benefits, the company said.
More Eli Lilly and Company News

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Head office United States
CEO David Ricks
Employees 43,000
Founded 1876
Website www.lilly.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today